FOLH1 and prostate cancer: Labeling with the positron-emitter Ga-68 facilitates PET imaging for detection of prostate cancer lesions [6] and labeling with the beta-emitting radionuclide Lu-177 enables PSMA-targeted radionuclide therapy.